NIKKEI 225
38,630.75 -2.27 (-0.01%) HANG SENG
18,021.56 -313.76 (-1.71%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.70 +7.70 (+0.33%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,980.05 -601.46 (-1.17%)
BetterLife Pharma Inc (NPAU.MU)
| Previous close | 0.0795 |
| Open | 0.0795 |
| Bid | 0.0750 x N/A |
| Ask | 0.0930 x N/A |
| Day's range | 0.0795 - 0.0795 |
| 52-week range | 0.0405 - 0.0795 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 26 Jun 2024 - 01 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBetterLife Announces Closing of a Private Placement
VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has closed a non-brokered private placement, previously announced on May 3, 2024, pursuant to which the Company issued 5,300,000 units (“Units”) at a price of $0.10 per Unit for aggrega
- GlobeNewswire
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials di
- GlobeNewswire
BetterLife Announces Intent to Complete Private Placement of Units
VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000. The Company intends to use the proceeds for the advancement
